Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
This study has been completed.
Study NCT00560313   Information provided by Novartis
First Received: November 16, 2007   Last Updated: November 16, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Meningococcal Disease
Additional conditions recognized in this trial
Meningococcal Infections
More general conditions related to this trial
Bacterial Infections
Gram-Negative Bacterial Infections
Neisseriaceae Infections
Interventions listed in this trial
Serogroup B meningococcal Vaccine
Sponsors listed in this trial
Novartis
Novartis Vaccines


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services